Enzymatica and STADA extend agreement on ViruProtect to Russia, Poland, Ukraine and CIS countries
Enzymatica has licensed to STADA exclusive rights to market and sell the common cold spray ViruProtect® (ColdZyme®) in Russia, Poland, Ukraine and 11 further countries in the CIS and Central Asia. The agreement builds on the two companies’ existing successful partnership to market ViruProtect, a locally-acting medical device treating and alleviating common cold, in more than 20 European countries. Russia, Poland, Ukraine and the other CIS countries represent large and growing consumer healthcare markets in which STADA has a substantial commercial footprint and sales and marketing